A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Tumors With Bone Only Metastasis

Interventions

DRUG

ALMB-0168

ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.

All Listed Sponsors

lead

AlaMab Therapeutics (Shanghai) Inc.

INDUSTRY